Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948513 | 0.91 | JAK3 (0.41) | HRH3RIPK1CYP2D6JAK3SMN1; SMN2 | |
| SCHEMBL9948893 | 0.89 | JAK3 (0.44) | RIPK1CYP2D6JAK3SMN1; SMN2 | |
| SCHEMBL22104901 | 0.81 | CYP2D6 (0.46) | HTR2AHTR2CHTR2BRIPK1CYP2D6 | |
| SCHEMBL22104899 | 0.73 | CYP2D6 (0.51) | RIPK1CYP2D6SMN1; SMN2 | |
| SCHEMBL9949153 | 0.73 | SMN1; SMN2 (0.33) | RIPK1SMN1; SMN2 | |
| SCHEMBL24922545 | 0.71 | NPC1 (0.49) | RIPK1SMN1; SMN2 | |
| SCHEMBL1961155 | 0.71 | HSP90AA1 (0.38) | — | |
| SCHEMBL5174301 | 0.70 | ELANE (0.43) | HTR2CHTR2BRIPK1 | |
| SCHEMBL10575296 | 0.70 | HCAR2 (0.50) | HTR2AHTR2CHTR2BHRH3CYP2D6 | |
| SCHEMBL366002 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | HTR2A 2733/4885HTR2C 2219/4885HTR2B 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.